Compare Gilead Sciences, Inc. (GILD) vs iShares Russell 2000 ETF (IWM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares Russell 2000 ETF — how do they compare? Gilead Sciences, Inc. trades at $133.51 (market cap $163.51B), while iShares Russell 2000 ETF trades at $296.15. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares Russell 2000 ETF pays none, and iShares Russell 2000 ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | IWM | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | — |
52-Week High | $155.80 | $300.45 |
52-Week Low | $108.22 | $214.95 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
IWM trades at $295.80, up 0.46% with a bullish technical signal from moving averages. The ETF has gained 22.1% year-to-date, outperforming large-cap benchmarks. Recent news highlights small-cap strength amid shifting rate expectations, though some analysts warn of valuation traps. Support sits at $294 with resistance at $297.
Outlook remains positive for small-cap exposure if economic expansion continues, but risks include higher volatility and sensitivity to interest rates. The expense ratio of 0.19% compares to peers, and dividend yield is minimal. Investors should weigh growth potential against inherent small-cap risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →
